The CASP9 Knockout Huh-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from Huh-7 cells, featuring targeted disruption of the CASP9 gene. This loss-of-function model enables robust population-level studies of the intrinsic apoptotic pathway. The polyclonal format provides a genetically heterogeneous pool of knockout alleles, suitable for applications requiring stable caspase-9 deficiency.
The parental Huh-7 line was established from a 57-year-old Japanese male hepatocellular carcinoma and displays epithelial morphology. It is a widely used model for liver cancer biology, including tumorigenesis, drug metabolism, and signal transduction. With intact apoptotic machinery and a p53 point mutation, Huh-7 offers a clinically relevant context for dissecting caspase-9 function in hepatocarcinoma.
CASP9 encodes the initiator caspase of the intrinsic apoptosis pathway. Mitochondrial cytochrome c release and binding to APAF1 triggers apoptosome assembly and procaspase-9 activation. Active caspase-9 cleaves executioner caspases CASP3 and CASP7, leading to substrate proteolysis. This cascade is modulated by BCL2 family members (BAX, BAK, BCL2, BCL-XL) and the inhibitor XIAP. AKT1 and MAPK3 signaling further regulates the pathway, while downstream targets include PARP1, DFFA, LMNA, and ROCK1, linking caspase-9 to apoptotic hallmarks. The interplay between caspase-9 and its interacting partners, including SMAC and HSP90AA1, further illustrates its central role in apoptosome regulation.
In hepatocellular carcinoma, apoptosis dysregulation promotes tumor progression and chemoresistance. CASP9 knockout in Huh-7 enables dissection of intrinsic apoptosis contributions independent of p53, which is frequently mutated in liver cancer. This model facilitates study of synthetic lethal interactions with oncogenic drivers and evaluation of therapeutics that engage mitochondrial death pathways.
Applications include signaling studies, drug sensitivity screening, and identification of caspase-9 bypass mechanisms. Compatible assays encompass caspase-9 activity measurement, western blotting, RT-qPCR, annexin V flow cytometry, TUNEL, and mitochondrial membrane potential assays. Additionally, these cells are valuable for CRISPR-based functional genomics screens and for investigating non-apoptotic roles of caspase-9, such as in differentiation or inflammation. For custom requests or technical support, please contact Ascent Research.
